Biological-E COVID vaccines in India soon, government seals deal for 300 million doses
The Indian government has agreed to purchase 300 million doses of Biological-E COVID vaccinations in order to enhance the fight against the coronavirus.
According to sources, the government has agreed to pay 15 billion rupees to indigenous vaccine maker Biological-E for 300 million COVID-19 vaccine doses (USD 205.62 million).
The vaccine, which is presently through phase 3 clinical trials, is expected to be available in the coming months, according to a statement from the Ministry of Health.
Biological E Limited, situated in Hyderabad, has secured a deal with Providence Therapeutics Holdings Inc, a Canadian biotechnology company, for its COVID-19 vaccine, according to a Reuters report.The RBD protein sub-unit vaccine being produced by Biological-E in conjunction with the Canadian biotechnology company is expected to hit the Indian market in the coming months.
A bridging study for the vaccine will be conducted in India by Biological E. In Phase 1 and 2 clinical studies, the vaccine showed promising outcomes. Meanwhile, Biological E is developing a subunit vaccine candidate of its own. It has completed Phase I/II clinical trials and received approval from the Central Drugs Standard Control Organization (CDSCO) - Subject Expert Committee to undertake Phase III clinical trials (SEC).Meanwhile, Biological E is developing a subunit vaccine candidate of its own. It has completed Phase I/II clinical trials and received approval from the Central Drugs Standard Control Organization (CDSCO) - Subject Expert Committee to undertake Phase III clinical trials (SEC).
By mid-July or early August, India will have enough COVID-19 vaccine doses to inoculate up to one crore people every day, the government said on Tuesday, stressing that there is no scarcity of vaccines and urging patience due to the country's large population.India increased testing and containment, which worked, but there are still 239 districts with more than 10% positivity, 145 districts with a positivity of 5 to 10%, and 350 districts, over half of India, with less than 5% case positive.